Bianca Previdi
Psychiatry · Philadelphia, PANPI 1902060486
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,175 of the $28,173 with a category attached, or 82.3%. AbbVie accounts for 89.3% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $24,213, more than ten times the $508 reported in 2019. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $121.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Otsuka America Pharmaceutical, Inc.$713
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$500
- Axsome Therapeutics, Inc.$412
- Alkermes, Inc.$347
- Sunovion Pharmaceuticals Inc.$319
- plus $734 from 7 others
What the payments were for
- Speaking & faculty fees$23,17582%
- Travel & lodging$850%
- Food & beverage$4,91017%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 126 | $25,147 |
| Otsuka America Pharmaceutical, Inc. | 17 | $713 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $500 |
| Axsome Therapeutics, Inc. | 12 | $412 |
| Alkermes, Inc. | 16 | $347 |
| Sunovion Pharmaceuticals Inc. | 14 | $319 |
| Neurocrine Biosciences, Inc. | 4 | $293 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $113 |
| Indivior Inc. | 5 | $86 |
| Johnson & Johnson | 3 | $85 |
| Braeburn Inc. | 4 | $79 |
| Avanir Pharmaceuticals, Inc. | 3 | $59 |
| Lundbeck LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,173 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,295 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $1,561 |
| Dextroamphetamine Sulfate | 12 | $271 |
| Aripiprazole | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $113 | $4,29511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Philadelphia
- Daniel WeintraubPhiladelphia$647K
- Michael ThasePhiladelphia$396K
- Freddy AliPhiladelphia$107K
- Richard JaffePhiladelphia$101K
- Ramesh EluriPhiladelphia$85K
- John LaurielloPhiladelphia$62K
- Sidra GhafoorPhiladelphia$56K
- Maria OquendoPhiladelphia$50K
- David OslinPhiladelphia$30K
- Steven ArnoldPhiladelphia$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.